The Global Market for AI BMS was estimated to be worth USD 6512 Million in 2023 and is forecast to a readjusted size of USD 17320 Million by 2030 with a CAGR of 15.0% during the forecast period ...

Bristol Myers Squibb (BMS) and 2seventy bio have announced plans ... The trial aimed to evaluate Abecma in combination with lenalidomide maintenance versus lenalidomide maintenance alone post ...

For BMS, the data positions CC-486 into a segment ... Roche and AbbVie are running a phase 2 trial on the go that is looking at Venclexta maintenance after first-line induction therapy with ...

BMS is looking to Onureg to restore the franchise, and analysts at GlobalData have predicted that the drug is set to become the standard first-line maintenance therapy for patients over 55 years ...